Mechanisms of mindfulness-based cognitive therapy in difficult-to-treat depression: moderation and mediation analyses from the RESPOND trial.
Thorsten Barnhofer, Barnaby D. Dunn, Clara Strauss, Florian A Ruths, Mary Ryan, Asha Ladwa, Frances Stafford, Roberta Fichera, Isabella Metcalfe, Allan H. Young, Kimberley Goldsmith
Psychological Medicine July 13, 2026 DOI: 10.1017/s0033291726105212 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Secondary moderation, mediation, and moderated mediation analyses of a randomized trial Peer reviewed |
|---|---|
| Sample size | 234 |
| Population | Adults with difficult-to-treat depression not remitted after high-intensity psychological therapy |
| Duration | 10-week intervention, 34-week follow-up |
| Topics | Depression Meditation |
| Keywords | Decentering Difficult-to-treat Mechanisms Mindfulness-based cognitive therapy Moderated mediation Moderation Symptom severity |
| Key findings | Baseline depressive severity did not moderate the treatment effect of MBCT, but it moderated the indirect effect through decentering, with decentering more strongly associated with symptom reduction among those with higher baseline depression. |
Abstract
Mindfulness-based cognitive therapy (MBCT) was developed for relapse prevention in people with remitted depression but is increasingly used for those with difficult-to-treat depression (DTD). A key question regarding this broader application is whether ongoing depressive symptoms constrain therapeutic responsiveness or disrupt MBCT's proposed mechanism, decentering. We explored whether baseline depressive severity moderates clinical outcomes, whether changes in decentering mediate treatment effects, and whether this mediation varies by baseline severity. Secondary moderation, mediation, and moderated mediation analyses were conducted using data from the RESPOND randomized trial (N = 234), comparing MBCT plus treatment as usual (TAU) with TAU alone in adults not remitted after high-intensity psychological therapy. Depressive symptoms (PHQ-9) and decentering (Experiences Questionnaire) were assessed at baseline, post-treatment (10 weeks), and follow-up (34 weeks). Analyses were conducted using structural equation modelling. Higher baseline severity predicted greater symptom improvement across both groups. Treatment-related increases in decentering partially mediated the effect of MBCT on depressive symptoms at follow-up. Although baseline severity did not moderate the treatment effect, it moderated the indirect effect, with decentering more strongly associated with symptom reduction among those with higher baseline depression. Severity did not moderate the acquisition of decentering skills. Concerns that more severe depressive symptoms limit the effectiveness of MBCT were not supported. MBCT's core mechanism remained operative under substantial symptom burden, with clinical impact amplified at higher severity. These findings reduce key uncertainties regarding the application of MBCT in DTD and support its use across a broad range of symptom severity.